EpistemisSynthesis and clinical application pearls
This vademecum concludes by integrating the reviewed drugs into a simplified analytical algorithm for daily clinical decision-making, facilitating rapid recognition of critical interactions and dynamic adjustment guidelines by the doctor.
File
| Active Drug | Main Target | Critical Hazard / Major Adjustment | Gestational Category (FDA) |
|---|---|---|---|
| Omeprazole / Esomeprazole | H+/K+-cellular apical ATPase | Potent inhibition of CYP2C19. Reduces clopidogrel activation. | Category C / B |
| Famotidine | Parietal basolateral H2 receptor | Rapid development of tachyphylaxis. Adjust to eGFR < 50 mL/min due to central neurotoxicity. | Category B |
| Sucralfate | Necrotic ulcer crater (Physical) | It decreases oral absorption of almost all drugs by physical chelation. Avoid in GFR < 30 due to aluminum. | Category B |
| Misoprostol | Receiver EP3 coupled to Gi | Absolute teratogenicity and abortive effect. Contraindicated in pregnant women. | Category X |
| Metoclopramide | Central and peripheral D2 antagonist | Acute extrapyramidal reactions and tardive dyskinesia. Reduce by 50% in eGFR < 50. | Category B |
| Domperidone | Peripheral selective D2 antagonist | Cardiotoxicity (QTc hERG prolongation). Prohibited with strong CYP3A4 inhibitors. | Category C |
| Linaclotide | Guanylate Cyclase C Agonist | Absolutely contraindicated in children under 6 years of age (severe fatal dehydration). | Category C |
| Ondansetron | 5-HT3 receptor antagonist | Maximum dose of 8 mg per day in Child-Pugh C. Risk of orofacial malformations in the 1st trimester. | Category B (Avoid 1st trimester) |
| Aprepitant | Substance P NK1 receptor antagonist | Moderate CYP3A4 inhibitor. It requires reducing the dose of dexamethasone by 50%. | Category B |
| Mesalazine | PPAR-γ and COX/5-LOX inhibition | Inhibits TPMT (severely increases azathioprine myelotoxicity). Idiosyncratic interstitial nephritis. | Category B |
| Azathioprine | Fake Thioguanine Nucleotides (6-TGN) | Lethal myelosuppression with allopurinol (reduce dose to 25%). Requires TPMT genotype. | Category D (Safe in moderate IBD) |
| Rifaximin | Bacterial RNA Polymerase (Local) | Systemic absorption of 0.4%. Indicated in hepatic encephalopathy and IBS-D. | Category C |
Gold summary in Gastrointestinal Therapeutics
Three critical guidelines unify the gastric and intestinal vademecum:
- The pH factor: Suppression of stomach acidity (using PPIs or antacids) alters the solubility, ionization and bioavailability of multiple acid-dependent drugs. Administrations must be spaced at least 2 hours apart.
- Myelosuppression by combination: The combination of aminosalicylates (mesalazine) with purine immunomodulators (azathioprine) enhances the toxicity of the latter due to cross-inhibition of the TPMT enzyme. The blood count should be closely monitored.
- Latent cardiotoxicity: Prokinetic and antiemetic drugs (domperidone, metoclopramide, ondansetron) are capable of synergistically prolonging the cardiac QTc interval. Avoid combining two or more drugs from these families in elderly patients with cardiovascular risk.
Accurate pharmacological judgment requires precise understanding of the parietal cell, myenteric receptors and microsomal metabolic pathways.
Epistemis is educational review material. It is not a medical device, does not diagnose or prescribe treatment, and does not replace formal medical training, current clinical guidelines, or professional clinical judgment.
- System
- Gastrointestinal
- Cluster
- Analysis of Clinical Cases and Adjustment Algorithms